AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18043573 — intervention group
Group type: COMPARATOR
Intervention: Metallic clips
Number of subjects: 310
Study 16086602 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS)
Number of subjects: 100
Study 12122096 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF followed by tamoxifen (20 mg/day, orally for 57 months)
Number of subjects: 1669
Study 12122096 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen alone (20 mg/day, orally for 60 months)
Number of subjects: 1669
Study 12024388 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone therapy
Number of subjects: 0
Study 7675685 — intervention group
Group type: EXPERIMENTAL
Intervention: Priority ranking of research topics
Number of subjects: 2178
Study 31784410 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepping Stones and Creating Futures intervention
Number of subjects: 1322
Study 31784410 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 1322
Study 31455407 — intervention group
Group type: EXPERIMENTAL
Intervention: C5 to C7 nerve root block
Number of subjects: 74
Study 31455407 — intervention group
Group type: EXPERIMENTAL
Intervention: C5 to C8 nerve root block
Number of subjects: 74
Study 27084245 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA screening
Number of subjects: 7539
Study 27084245 — intervention group
Group type: COMPARATOR
Intervention: Unscreened men
Number of subjects: 7539
Study 26305648 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity program (n = 818)
Number of subjects: 1635
Study 26305648 — intervention group
Group type: COMPARATOR
Intervention: Health education program (n = 817)
Number of subjects: 1635
Study 26305648 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity group (n = 307, aged 80 or older)
Number of subjects: 1635
Study 26305648 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity group (n = 328, poorer baseline physical performance)
Number of subjects: 1635
Study 26305648 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity group
Number of subjects: 1635
Study 26305648 — intervention group
Group type: COMPARATOR
Intervention: Health education group
Number of subjects: 1635
Study 27536443 — intervention group
Group type: EXPERIMENTAL
Intervention: LCTZ plus FFNS (combination group)
Number of subjects: 42
Study 27536443 — intervention group
Group type: EXPERIMENTAL
Intervention: LCTZ plus FFNS placebo (monotherapy group)
Number of subjects: 42
Study 27536443 — intervention group
Group type: COMPARATOR
Intervention: LCTZ placebo plus FFNS placebo (placebo group)
Number of subjects: 42
Study 21778153 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy smokers who abstained from smoking for 12 hr
Number of subjects: 54
Study 21778153 — intervention group
Group type: COMPARATOR
Intervention: Heavy smokers who smoked as usual
Number of subjects: 54
Study 19963158 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg pequi oil capsules for 14 days
Number of subjects: 0
Study 19963158 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 16930785 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 40
Study 16930785 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam with Remifentanil
Number of subjects: 40
Study 15472177 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone (20 mg/d; n = 20)
Number of subjects: 32
Study 11720432 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care intervention
Number of subjects: 395
Study 9791142 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine and Lamivudine
Number of subjects: 378
Study 9791142 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine and Indinavir
Number of subjects: 378
Study 9791142 — intervention group
Group type: COMPARATOR
Intervention: Triple-drug therapy (Zidovudine, Lamivudine, and Indinavir)
Number of subjects: 378
Study 7820985 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg/day telmestein
Number of subjects: 20
Study 7820985 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 3059703 — intervention group
Group type: EXPERIMENTAL
Intervention: pirenzepine 50 mg b.i.d. (n = 24)
Number of subjects: 43
Study 3059703 — intervention group
Group type: COMPARATOR
Intervention: cimetidine 400 mg b.i.d. (n = 19)
Number of subjects: 43
Study 3059703 — intervention group
Group type: EXPERIMENTAL
Intervention: pirenzepine 50 mg b.i.d. or cimetidine 400 mg b.i.d.
Number of subjects: 43
Study 31963904 — intervention group
Group type: EXPERIMENTAL
Intervention: Fundamental motor skill focus (FMS)
Number of subjects: 98
Study 31963904 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity focus (PA)
Number of subjects: 98
Study 31963904 — intervention group
Group type: EXPERIMENTAL
Intervention: FMS and PA (FMS + PA)
Number of subjects: 98
Study 31963904 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 98
Study 30328064 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etch primed sealant (Beautisealant, Shofu)
Number of subjects: 81
Study 30328064 — intervention group
Group type: COMPARATOR
Intervention: Conventional etch and rinse sealant (Seal it, Spident)
Number of subjects: 81
Study 29098263 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain management intervention measures
Number of subjects: 100
Study 29098263 — intervention group
Group type: COMPARATOR
Intervention: Conventional nursing care (Control)
Number of subjects: 100
Study 26245807 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavone oral supplements (2 doses of a genistein-rich soy supplement and 3 doses of mixed isoflavones)
Number of subjects: 24
Study 26245807 — intervention group
Group type: COMPARATOR
Intervention: Risedronate (bisphosphonate)
Number of subjects: 24
Study 26245807 — intervention group
Group type: EXPERIMENTAL
Intervention: Genistein at 52.85 mg/d
Number of subjects: 24
Study 26245807 — intervention group
Group type: EXPERIMENTAL
Intervention: Most effective soy intervention (105.23 mg total isoflavones/d)
Number of subjects: 24
Study 23864314 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthalamic nuclei deep brain stimulation (STN‐DBS)
Number of subjects: 19
Study 23864314 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa administration
Number of subjects: 19
Study 23864314 — intervention group
Group type: COMPARATOR
Intervention: Stimulation off/medication off (control condition)
Number of subjects: 19
Study 23864314 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic STN‐DBS
Number of subjects: 19
Study 20506561 — intervention group
Group type: EXPERIMENTAL
Intervention: RA scores (DAS, DAS in 28 joints, Simplified Disease Activity Index, Clinical Disease Activity Index)
Number of subjects: 97
Study 20506561 — intervention group
Group type: EXPERIMENTAL
Intervention: JADAS (10-, 27-, and 71-joint counts)
Number of subjects: 97
Study 18192341 — intervention group
Group type: EXPERIMENTAL
Intervention: Bachmann's bundle (BB) area
Number of subjects: 139
Study 18192341 — intervention group
Group type: COMPARATOR
Intervention: Right atrial appendage (RAA) area
Number of subjects: 139
Study 16344495 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide treatment
Number of subjects: 7
Study 16344495 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 7
Study 14736007 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal artery stent placement with medication (statins, anti-hypertensive drugs, antiplatelet therapy)
Number of subjects: 140
Study 14736007 — intervention group
Group type: COMPARATOR
Intervention: Medication alone (statins, anti-hypertensive drugs, antiplatelet therapy)
Number of subjects: 140
Study 11040223 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinamap oscillometric blood pressure monitor
Number of subjects: 1808
Study 11040223 — intervention group
Group type: COMPARATOR
Intervention: random‐zero sphygmomanometer
Number of subjects: 1808
Study 8651094 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (1.25 to 20 mg/day)
Number of subjects: 1055
Study 8651094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1055
Study 1740589 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal provocation with allergen
Number of subjects: 0
Study 1740589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6384250 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% CHO diet with 15% sucrose (60-15%)
Number of subjects: 10
Study 6384250 — intervention group
Group type: COMPARATOR
Intervention: 60% CHO diet with 13% sucrose (60-13%)
Number of subjects: 10
Study 6384250 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% CHO diet with 9% sucrose (40-9%)
Number of subjects: 10
Study 6384250 — intervention group
Group type: COMPARATOR
Intervention: 40% CHO diet with 13% sucrose (40-13%)
Number of subjects: 10
Study 31529662 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom balloon tamponade (CBT)
Number of subjects: 0
Study 31529662 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 28644716 — intervention group
Group type: COMPARATOR
Intervention: Water (W)
Number of subjects: 14
Study 28644716 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO)
Number of subjects: 14
Study 28644716 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine + Carbohydrate (CAF+CHO)
Number of subjects: 14
Study 28644716 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF)
Number of subjects: 14
Study 27542833 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotion of appropriate complementary feeding practices
Number of subjects: 611
Study 27542833 — intervention group
Group type: EXPERIMENTAL
Intervention: Child's age (12-17 and 18-23 months)
Number of subjects: 611
Study 27542833 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational level of mother (primary and secondary and above schools)
Number of subjects: 611
Study 27542833 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller family size
Number of subjects: 611
Study 24844734 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based parenting skills intervention with live coaching
Number of subjects: 7
Study 24844734 — intervention group
Group type: COMPARATOR
Intervention: Internet resources on brain injury
Number of subjects: 7
Study 22409354 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,064 nm laser-assisted liposuction and minimally invasive skin tightening
Number of subjects: 12
Study 22409354 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,319 nm laser-assisted liposuction and minimally invasive skin tightening
Number of subjects: 12
Study 22409354 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,064/1,319 nm laser-assisted liposuction and minimally invasive skin tightening
Number of subjects: 12
Study 22409354 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of all treatments (1,064 nm, 1,319 nm, and blended)
Number of subjects: 12
Study 20130150 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for abstinence
Number of subjects: 0
Study 20130150 — intervention group
Group type: COMPARATOR
Intervention: Preference for non-abstinence
Number of subjects: 0
Study 17035939 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low protein diet (VLPD) supplemented with ketoanalogs (0.35 g/kg/day)
Number of subjects: 110
Study 17035939 — intervention group
Group type: COMPARATOR
Intervention: Low protein diet (LPD, 0.60 g/kg/day)
Number of subjects: 110
Study 17035939 — intervention group
Group type: COMPARATOR
Intervention: Free diet (FD)
Number of subjects: 110
Study 17035939 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low protein diet (VLPD)
Number of subjects: 110
Study 15267124 — intervention group
Group type: EXPERIMENTAL
Intervention: Weak/Intentional
Number of subjects: 0
Study 15267124 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong/Intentional
Number of subjects: 0
Study 15267124 — intervention group
Group type: EXPERIMENTAL
Intervention: Weak/Incidental
Number of subjects: 0
Study 15267124 — intervention group
Group type: COMPARATOR
Intervention: Strong/Incidental
Number of subjects: 0
Study 11381492 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymosin alpha-1 (TA1)
Number of subjects: 357
Study 11381492 — intervention group
Group type: COMPARATOR
Intervention: Thymosin alpha-1 (TA1) for 6 months
Number of subjects: 357
Study 11381492 — intervention group
Group type: COMPARATOR
Intervention: Thymosin alpha-1 (TA1) for 12 months
Number of subjects: 357
Study 11381492 — intervention group
Group type: COMPARATOR
Intervention: Combination TA1 and IFN-alpha 2b
Number of subjects: 357
Study 9815011 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (48 g)
Number of subjects: 10
Study 9815011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8017602 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal cannulae
Number of subjects: 20
Study 8017602 — intervention group
Group type: COMPARATOR
Intervention: Complete nasal obstruction
Number of subjects: 20
Study 2582983 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental stress (induced by solving anagrams and doing mental arithmetic for 60 min)
Number of subjects: 12
Study 2582983 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental stress
Number of subjects: 12
Study 779692 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral disopyramide administered during 7 days
Number of subjects: 20
Study 779692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31477152 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (162 mg daily for 2 weeks)
Number of subjects: 25
Study 31477152 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg daily for 2 weeks)
Number of subjects: 25
Study 31477152 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (Aspirin 162 mg and Pravastatin 40 mg daily for 2 weeks)
Number of subjects: 25
Study 28314622 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 90
Study 27049526 — intervention group
Group type: EXPERIMENTAL
Intervention: 25(OH)D concentrations ≥40 ng/ml
Number of subjects: 2304
Study 27049526 — intervention group
Group type: COMPARATOR
Intervention: 25(OH)D concentrations <20 ng/ml
Number of subjects: 2304
Study 24783469 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure therapy (CPAP) for 24 weeks
Number of subjects: 117
Study 23094120 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel (PZQ) treatment
Number of subjects: 369
Study 19232573 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 0
Study 19232573 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 0
Study 18089249 — intervention group
Group type: EXPERIMENTAL
Intervention: Downward social comparison
Number of subjects: 0
Study 18089249 — intervention group
Group type: COMPARATOR
Intervention: Upward social comparison
Number of subjects: 0
Study 18089249 — intervention group
Group type: COMPARATOR
Intervention: No comparison
Number of subjects: 0
Study 18089249 — intervention group
Group type: EXPERIMENTAL
Intervention: Appearance self-schema priming
Number of subjects: 0
Study 18089249 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-appearance schema priming
Number of subjects: 0
Study 15204676 — intervention group
Group type: EXPERIMENTAL
Intervention: Office-based methadone maintenance
Number of subjects: 0
Study 15204676 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus group discussions
Number of subjects: 0
Study 15204676 — intervention group
Group type: EXPERIMENTAL
Intervention: Chart audits and mentoring
Number of subjects: 0
Study 15204676 — intervention group
Group type: EXPERIMENTAL
Intervention: Processes of care
Number of subjects: 0
Study 11337315 — intervention group
Group type: EXPERIMENTAL
Intervention: Saw Palmetto Herbal Blend (SPHB)
Number of subjects: 66
Study 11337315 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 66
Study 11337315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 9505161 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (280 mg daily for 10 weeks)
Number of subjects: 60
Study 9505161 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 60
Study 7785553 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin for 7 days after ESWL (Group A, n = 66)
Number of subjects: 161
Study 7785553 — intervention group
Group type: COMPARATOR
Intervention: No antimicrobial (Group B, n = 67)
Number of subjects: 161
Study 7785553 — intervention group
Group type: EXPERIMENTAL
Intervention: Flomoxef intravenously for 2 or 3 days and ofloxacin for 4 or 5 days thereafter (Group C, n = 10)
Number of subjects: 161
Study 7785553 — intervention group
Group type: EXPERIMENTAL
Intervention: Flomoxef only for 2 or 3 days and no drugs later (Group D, n = 10)
Number of subjects: 161
Study 7785553 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin for 7 days (Group E, n = 8)
Number of subjects: 161
Study 2186055 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS 201-995
Number of subjects: 26
Study 2186055 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine
Number of subjects: 26
Study 372839 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment (therapeutic serum levels of 0.7-1.1 mmol/L)
Number of subjects: 0
Study 372839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31980913 — intervention group
Group type: EXPERIMENTAL
Intervention: DC vaccination with cisplatin
Number of subjects: 54
Study 31980913 — intervention group
Group type: COMPARATOR
Intervention: DC vaccination without cisplatin
Number of subjects: 54
Study 31980913 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (DC vaccination + cisplatin)
Number of subjects: 54
Study 31151333 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex Decongestive Therapy (CDT) - 10 sessions over 2 weeks
Number of subjects: 38
Study 31151333 — intervention group
Group type: COMPARATOR
Intervention: Stellate Ganglion Block (SGB) - 3 consecutive blocks every 2 weeks
Number of subjects: 38
Study 31151333 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Life measures (EQ-5D and EQ VAS)
Number of subjects: 38
Study 27756513 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated CPR using the Lifeline ARM
Number of subjects: 78
Study 27756513 — intervention group
Group type: COMPARATOR
Intervention: Manual CPR
Number of subjects: 78
Study 25888111 — intervention group
Group type: EXPERIMENTAL
Intervention: Midline incision
Number of subjects: 20
Study 25888111 — intervention group
Group type: EXPERIMENTAL
Intervention: Paramedian incision
Number of subjects: 20
Study 25888111 — intervention group
Group type: COMPARATOR
Intervention: Both incision types
Number of subjects: 20
Study 24392996 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection-site warming device (InsuPad)
Number of subjects: 145
Study 24392996 — intervention group
Group type: COMPARATOR
Intervention: Control group (no warming device)
Number of subjects: 145
Study 22560125 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypodium leucotomos extract
Number of subjects: 105
Study 22560125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 19362013 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 30
Study 19362013 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil
Number of subjects: 30
Study 17985398 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental intervention (84.6% of abstracts explicitly described this)
Number of subjects: 143
Study 17985398 — intervention group
Group type: COMPARATOR
Intervention: Comparator intervention (37.1% of abstracts explicitly described this)
Number of subjects: 143
Study 17985398 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention to treat analysis
Number of subjects: 143
Study 17985398 — intervention group
Group type: EXPERIMENTAL
Intervention: Effect size reporting
Number of subjects: 143
Study 17985398 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinding information
Number of subjects: 143
Study 17985398 — intervention group
Group type: EXPERIMENTAL
Intervention: Eligibility criteria
Number of subjects: 143
Study 15650515 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 82
Study 15650515 — intervention group
Group type: COMPARATOR
Intervention: Unoprostone
Number of subjects: 82
Study 12126907 — intervention group
Group type: EXPERIMENTAL
Intervention: RV3 vaccine (6.5 x 10(5) fcfu)
Number of subjects: 0
Study 12126907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9818858 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Number of subjects: 199
Study 9818858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study 7895551 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg lansoprazole once daily
Number of subjects: 54
Study 7895551 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg lansoprazole once daily
Number of subjects: 54
Study 2702840 — intervention group
Group type: EXPERIMENTAL
Intervention: Trendelenburg position (TREND) at 20 degrees
Number of subjects: 18
Study 2702840 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive leg raising (PLR) at 60 degrees
Number of subjects: 18
Study 284719 — intervention group
Group type: EXPERIMENTAL
Intervention: Propylthiouracil (both intravenous and oral administration)
Number of subjects: 9
Study 284719 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphical method for calculating kinetics parameters
Number of subjects: 9
Study 284719 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer program for calculating kinetics parameters
Number of subjects: 9
Study 284719 — intervention group
Group type: COMPARATOR
Intervention: Comparison between age groups
Number of subjects: 9
Study 31134274 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapeseed expeller cake (REC) at 7% and 14% from DY6, DY5, MB1, and XH3 varieties
Number of subjects: 1080
Study 31134274 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapeseed expeller cake (REC)
Number of subjects: 1080
Study 31134274 — intervention group
Group type: EXPERIMENTAL
Intervention: XH3 REC
Number of subjects: 1080
Study 31134274 — intervention group
Group type: EXPERIMENTAL
Intervention: DY6 REC
Number of subjects: 1080
Study 31134274 — intervention group
Group type: EXPERIMENTAL
Intervention: XH3, MB1, and DY5 REC
Number of subjects: 1080
Study 31134274 — intervention group
Group type: EXPERIMENTAL
Intervention: XH3 and DY5 REC
Number of subjects: 1080